The research network, led by Leibniz Universität Hannover, focuses on linking biologisation and digitalisation in the sense of an overall societal ‘Great Transformation’ towards sustainable, bio-based innovation in interdisciplinary and cross-industry approaches. Priority is given to digital structures and architectures based on artificial intelligence to support the biologisation of processes and products. The IJK is responsible for overarching research into social perception and participation for all three industry worlds of personalised medicine & medical technology (A), pharmaceuticals (B) and food & fine chemicals (C).

In the industry world of personalised medicine and medical technology, [HC]² uses the example of cancer diagnostics and therapy recommendations to address the question of when and under what circumstances such new developments are (not) accepted. Digital structures and platforms for pooling patient data and linking it with bio-inspired diagnostics and new imaging procedures form the nucleus for patient-individualised therapy recommendations. Personalised medicine harbours enormous potential for differential diagnostics and thus precisely tailored and effective therapies that can reduce the risks of overuse, underuse and misuse. At the same time, it demands additional specialist and mediation skills from healthcare professionals and additional decision-making processes from patients. With the help of a mixed-method study, we would therefore like to identify barriers to information and the use of personalised medicine.

Prof. Dr. Eva Baumann
Prof. Dr. Christoph Klimmt
Tanja Fisse
Dr. Magdalena Rosset
Charlotte Schrimpff
Nico Spreen

January 2022 to June 2025